Mendel Capital Management LLC Has $531,000 Position in The Clorox Company (NYSE:CLX)

Mendel Capital Management LLC increased its position in The Clorox Company (NYSE:CLX) by 8.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,261 shares of the company’s stock after buying an additional 267 shares during the period. Mendel Capital Management LLC’s holdings in Clorox were worth $531,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Clorox by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 15,277,580 shares of the company’s stock valued at $2,339,150,000 after acquiring an additional 48,632 shares in the last quarter. Mizuho Securities USA LLC lifted its stake in Clorox by 46,877.8% in the third quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after purchasing an additional 4,490,421 shares during the last quarter. Nuance Investments LLC grew its stake in shares of Clorox by 150.6% during the 2nd quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock worth $218,035,000 after acquiring an additional 960,094 shares during the period. Van ECK Associates Corp increased its stake in shares of Clorox by 2.2% in the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock worth $237,372,000 after purchasing an additional 31,510 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Clorox by 14.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock valued at $131,200,000 after buying an additional 120,716 shares in the last quarter. 78.53% of the stock is owned by institutional investors.

Clorox Price Performance

Shares of CLX opened at $167.64 on Monday. The firm’s 50-day simple moving average is $162.45 and its two-hundred day simple moving average is $147.52. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $169.09. The stock has a market cap of $20.75 billion, a PE ratio of 58.41, a price-to-earnings-growth ratio of 3.10 and a beta of 0.41. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.50. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The company had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same quarter last year, the company earned $0.49 EPS. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. Analysts anticipate that The Clorox Company will post 6.85 earnings per share for the current fiscal year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd were given a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 2.91%. The ex-dividend date of this dividend was Wednesday, October 23rd. Clorox’s dividend payout ratio (DPR) is 170.03%.

Insider Buying and Selling at Clorox

In related news, EVP Angela C. Hilt sold 1,733 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the sale, the executive vice president now owns 13,471 shares of the company’s stock, valued at $2,229,719.92. This trade represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CLX shares. Evercore ISI decreased their price target on Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research report on Monday, October 14th. Citigroup lifted their price target on Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Barclays increased their target price on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a report on Friday, November 1st. TD Cowen raised Clorox from a “sell” rating to a “hold” rating and lifted their price target for the stock from $155.00 to $170.00 in a research note on Wednesday, November 6th. Finally, DA Davidson upped their price objective on shares of Clorox from $153.00 to $171.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Clorox currently has an average rating of “Hold” and an average price target of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.